Dysregulation of IL-32 in myelodysplastic syndrome and chronic myelomonocytic leukemia modulates apoptosis and impairs NK function

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 8, 2008, Pages 2865-2870

  Marcondes, A Mario ^a   Mhyre, Andrew J ^a   Stirewalt, Derek L ^a,b   Kim, Soo Hyun ^c   Dinarello, Charles A ^c   Deeg, H Joachim ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

Marrow stroma; TNF

Indexed keywords

CYTOKINE; INTERLEUKIN 2; INTERLEUKIN 32; MESSENGER RNA; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; CD56 ANTIGEN; IL32 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE;

APOPTOSIS; ARTICLE; BONE MARROW CELL; CELL FUNCTION; CHRONIC MYELOMONOCYTIC LEUKEMIA; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; LEUKEMIA CELL; MYELODYSPLASTIC SYNDROME; NATURAL KILLER CELL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; STROMA CELL; CELL LINE; COMPARATIVE STUDY; GENE EXPRESSION REGULATION; IMMUNOLOGY; METABOLISM; RNA INTERFERENCE;

CUCURBITA;

ANTIGENS, CD56; APOPTOSIS; BONE MARROW CELLS; CELL LINE; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKINS; KILLER CELLS, NATURAL; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MYELODYSPLASTIC SYNDROMES; RNA INTERFERENCE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 42949095542     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0712391105     Document Type: Article

References (35)

1. Deeg HJ (2007) in Thomas' Hematopoietic Cell Transplantation, eds Appelbaum FR, Forman SJ, Negrin RS, Blume KG (Blackwell, Oxford), 4th Ed.
2. de Lima M, Giralt, S (2006) Allogeneic transplantation for the elderly patient with acute myelogenous leukemia or myelodysplastic syndrome. Semin Hematol 43:107-117.
3. Mundle SD, et al. (1996) Indication of an involvement of interleukin-1 beta converting enzyme-like protease in intramedullary apoptotic cell death in the bone marrow of patients with myelodysplastic syndromes. Blood 88:2640-2647.
4. Gersuk GM, et al. (1998) A role for tumor necrosis factor-α, Fas and Fas-Ligand in marrow failure associated with myelodysplastic syndrome. Br J Haematol 103:176-188.
5. Zang DY, Goodwin RG, Loken MR, Bryant E, Deeg HJ (2001) Expression of tumor necrosis factor-related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: effects on in vitro hemopoiesis. Blood 98:3058-3065.
6. Bellamy WT, et al. (2001) Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood 97:1427-1434.
7. Deeg HJ, et al. (2004) Hematologic responses of patients with MDS to antithymocyte globulin plus etanercept correlate with improved flow scores of marrow cells. Leuk Res 28:1177-1180.
8. Li X, Bryant E, Deeg HJ (2004) Simultaneous demonstration of clonal chromosome abnormalities and apoptosis in individual marrow cells in myelodysplastic syndrome. Int J Hematol 80:140-145.
9. Kerbauy DMB, et al. (2005)NF-κB and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs). Blood 106:3917-3925.
10. Molldrem JJ, et al. (1998) Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles. Br J Haematol 102:1314-1322.
11. Deeg HJ, et al. (2000) Negative regulators of hemopoiesis and stroma function in patients with myelodysplastic syndrome. Leuk Lymphoma 37:405-414.
12. Stirewalt DL, et al. (2008) TNF induced gene expression in human marrow stroma: Clues to the pathophysiology of MDS. Br J Haematol 140:444-453.
13. Shioya M, et al. (2007) Epithelial overexpression of interleukin-32alpha in inflammatory bowel disease. Clin Exp Immunol 149:480-486.
14. Dinarello CA, Kim SH (2006) IL-32, a novel cytokine with a possible role in disease. Ann Rheum Dis 65(Suppl 3):iii61-iii64.
15. Joosten LA, et al. (2006) IL-32, a proinflammatory cytokine in rheumatoid arthritis. Proc Natl Acad Sci USA 103:3298-3303.
16. Netea MG, et al. (2005) IL-32 synergizes with nucleotide oligomerization domain (NOD) 1 and NOD2 ligands for IL-1beta and IL-6 production through a caspase 1-dependent mechanism. Proc Natl Acad Sci USA 102:16309-16314.
17. Kim SH, et al. (2005) Interleukin-32: A cytokine and inducer of TNFalpha. Immunity 22:131-142.
18. Bennett JM, et al. (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189-199.
19. Vardiman JW, Harris NL, Brunning RD (2002) The World Health Organization (WHO) classification of the myeloid neoplasm. Blood 100:2292-2302.
20. Allampallam K, et al. (2002) Biological significance of proliferation, apoptosis, cytokines, and monocyte/macrophage cells in bone marrow biopsies of 145 patients with myelodysplastic syndrome. Int J Hematol 75:289-297.
21. Molnar L, Berki T, Hussain A, Nemeth P, Losonczy H. (2000) Detection of TNFalpha expression in the bone marrow and determination of TNFalpha production of peripheral blood mononuclear cells in myelodysplastic syndrome. Pathol Oncol Res 6:18-23.
22. Raza A, et al. (1996) Novel insights into the biology of myelodysplastic syndromes: Excessive apoptosis and the role of cytokines. Int J Hematol 63:265-278.
23. Goda C, et al. (2006) Involvement of IL-32 in activation-induced cell death in T cells. Int Immunol 18:233-240.
24. Kitagawa M, et al. (1997) Overexpression of tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma by bone marrow cells from patients with myelodysplastic syndromes. Leukemia 11:2049-2054.
25. Ying SX, et al. (2007) Differential effects of bexatrone on intrinsic and extrinsic pathways in TRAIL-induced apoptosis in two myeloid leukemia cell lines. Leuk Lymphoma 48:1003-1014.
26. Broxmeyer HE, et al. (1995) Myeloid progenitor cell regulatory effects of vascular endothelial cell growth factor. Int J Hematol 62:203-215.
27. Dahl CA, Schall RP, He HL, Cairns JS (1992) Identification of a novel gene expressed in activated natural killer cells and T cells. J Immunol 148:597-603.
28. Kiladjian JJ, et al. (2006) Cytolytic function and survival of natural killer cells are severely altered in myelodysplastic syndromes. Leukemia 20:463-470.
29. Reza S, Shetty V, Dar S, Qawi H, Raza A (1998) Tumor necrosis factor-alpha levels decrease with anticytokine therapy in patients with myelodysplastic syndromes. J Interferon Cytokine Res 18:871-877.
30. Konopleva M, et al. (2002) Stromal cells prevent apoptosis of AML cells by upregulation of anti-apoptotic proteins. Leukemia 16:1713-1724.
31. Garrido SM, Appelbaum FR, Willman CL, Banker DE (2001) Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5). Exp Hematol 29:448-457.
32. Roth C, Rothlin C, Riou S, Raulet DH, Lemke G. (2007) Stromal-cell regulation of natural killer cell differentiation. J Mol Med DOI:10.1007/s00109-007-0195-0.
33. Roecklein BA, Torok-Storb B (1995) Functionally distinct human marrow stromal cell lines immortalized by transduction with the human papilloma virus E6/E7 genes. Blood 85:997-1005.
34. Koeffler HP, Billing R, Lusis AJ, Sparkes R, Golde DW (1980) An undifferentiated variant derived from the human acute myelogenous leukemia cell line (KG-1). Blood 56:265-273.
35. Graf L, Heimfeld S, Torok-Storb B (2001) Comparison of gene expression in CD34+ cells from bone marrow and G-CSF mobilized peripheral blood by high-density oligonucleotide array analysis. Biol Blood Marrow Transplant 7:486-494.